TET1 and neoplasm: TET1 loss in prostate cancer and breast cancer was found contributing to the hypermethylation of tissue inhibitors of metalloproteinases genes (TIMP2 and TIMP3), which resulted in the epithelial-mesenchymal transition (EMT) and tumor progression (Hsu et al., 2012).